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Tuberculosis (TB) poses a grave predicament to the world
as it is not merely a scientiﬁc challenge but a socio-economic
burden as well. A prime cause of mortality in human due to
an infectious disease; the malady and its cause,
Mycobacterium tuberculosis have remained an enigma with
many questions that remain unanswered. The ability of the
pathogen to survive and switch between varied physiological
states necessitates a protracted therapeutic regimen that
exerts an excessive strain on low-resource countries. To
complicate things further, there has been a signiﬁcant rise of
antimicrobial resistance. Existing control measures, including
treatment regimens have remained fairly uniform globally for
at least half a century and require reinvention. Overcoming
the societal and scientiﬁc challenges requires an increase in
dialog to identify key regions that need attention and
effective partners with whom successful collaborations can
be fostered. In this report, we explore the discussions held at
the International TB Summit 2015 hosted by EuroSciCon,
which served as an excellent platform for researchers to share
their recent ﬁndings. Ground-breaking results require
outreach to affect policy design, governance and control of
the disease. Hence, we feel it is important that meetings such
as these reach a wider, global audience.
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Introduction
Continuing its strong association and commitment toward
bringing attention to the infectious disease regarded as the
scourge of the poor and a health risk globally, EuroSciCon
(http://euroscicon.com/) held its third international TB Summit
in East London, UK.1,2 In this report, we strive to provide an
overview of the main topics and the key ideas covered by the oral
and poster presentations as well as the thought-provoking discus-
sion sessions that were a part of each day of the conference. The
three day conference brought together world-leading scientists,
clinicians, representatives from the industrial sector, students and
post-doctoral fellows for intensive sessions that aimed to bring
out emerging issues on tuberculosis (TB) that require immediate
global attention.
The importance of these annual events cannot be overlooked
as the death toll due to TB still averages at 1.5 million lives every
year.3 Although the causal organism of the disease, Mycobacte-
rium tuberculosis, was reported more than a century ago, scientific
progress has not matched up to its adaptability and versatility in
order to put this menace to an end. A three-pronged approach of
prevention, accurate diagnosis and effective treatment is essential
to overcome this disease.4 However, there are many bottlenecks
that impede development in all 3 areas. In the absence of vali-
dated, reliable biomarkers to judge the protective efficacy and
safety of new vaccine candidates we are left with Bacillus Calm-
ette-Guerin (BCG), the only vaccine available for the last hun-
dred years, even though it falls short of protecting populations
against active pulmonary TB.5
With more than a third of the world’s population latently
infected with TB, any chemo-prophylactic measures including
vaccines, that could assist the host’s immune system to remove
these dormant pathogen cells, is appreciated as crucial. Latent
TB infections (LTBI) are a potential health threat as they may
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revert to active infections due to immune-compromisation of the
primary host. However, molecular details of the host-pathogen
interplay that are instrumental in bringing about the physiologi-
cal switch are still largely unknown.6 For hundred years, the only
diagnostic technique to detect LTBI was the tuberculin skin test
(TST) until recently when interferon gamma (IFNg) release
assays (IGRA) were licensed for use. On the other hand, chest X-
rays, smear microscopy and sputum culture are the classical diag-
nostic techniques to detect active TB. However, these methods
make great demands on labor, time and resources. This is more
so when culture methods are used for drug susceptibility testing
(DST). With the advent of nucleic acid amplification tests
(NAAT), such as the GeneXpert, diagnosis of drug resistance
has become faster, however deployment of the PCR-based system
in resource-poor settings is still a distant goal.7,8
Misdiagnosis of the disease most often results in inappropriate
therapy which further exacerbates the issue of drug resistance in
the pathogen. Inadvertent mistakes in treatment can lead to selec-
tive pressures which are beneficial for strains that are already drug
resistant or ones which have a greater propensity to acquire them.
Thus, what was once considered a consequence of patient non-
compliance or a healthcare management-related issue is now forc-
ing us to rethink the ‘magic pill’ , standardised strategy of overtly
depending upon antibiotics. As deaths due to multi-drug and
extensively drug-resistant (MDR and XDR) TB keep increasing
the arsenal of novel therapeutic targets and new classes of antibac-
terial compounds needs to keep up the pace accordingly.
Rise of the ‘super strains’
Mycobacterium tuberculosis, the causal organism of TB is pre-
sumed to have originated in the Fertile Crescent and the areas
neighboring the African continent and migrated from there.9
Two of the 7 currently existing lineages of the pathogen still
remain in Africa, while the modern lineages have infiltrated
Africa by thoroughfare of infected individuals.10
The rise and spread of antibiotic resistance have very rightly
captured the attention of the masses. Drug-resistance in TB has
been rising and spreading throughout the world so much so that
there is at least one report of XDR-TB in 100 countries world-
wide at this present moment.3 Though many reasons have been
attributed to this rise of resistance, most of these have been
related to practices such as patient habits, incorrect diagnoses and
breakdown of nationalised healthcare systems.11 However,
advances in genotyping and strain identification have indicated
the predominance of some lineages over others in relation to their
ease of transmission to susceptible hosts.12 These fast-spreading
modern lineages have not only surpassed the ancient ones in
numbers but also appear to acquire resistance very successfully,
thereby deserving immediate attention as treatment options
remain limited.13 Dr R. Anthony, Royal Tropical Institute (The
Netherlands), a regular participant of the conference, divulged
details of his group’s investigation into the drug-resistance related
mutations in the Beijing-type strain of the pathogen. They gener-
ated several mutants in vitro that were resistant to the isoniazid
(INH), commonly used to treat TB. M. tuberculosis develops
drug resistance exclusively through chromosomal mutations, in
particular single-nucleotide polymorphisms.14,15 However, he
doubted that the mutants that are raised against a single drug in
the laboratory are, for the most part, representative of the resis-
tant organism infecting the host. Many of these lab-based
mutants cannot survive in a human patient as they either lose
their virulence or pathogenicity.16 Thus, there must be a low
number of mutations through which it is possible to retain path-
ogenicity and yet gain resistance. To detect these, the line probe
assays were used. Other than being elegant and simple, these are
highly sensitive in picking up specific alterations in selected
genes. It was observed that clinically relevant Beijing-type
mutants, when exposed to selective pressure by exposure to rifam-
picin (RIF) a first-line anti-TB drug, were more successful in
developing resistance to it compared to their non-Beijing coun-
terparts. A study in the Republic of Georgia, wherein numerous
strains were genotyped also showed a high association of multi-
drug resistance with Beijing strains.17 The interaction between
Beijing strains and RIF using specialized membrane-culture
methods teamed with customised microscopy revealed that these
strains may be intrinsically more insensitive toward the drug than
the other strains.18 This along with the previous findings that
these strains acquire mutations readily has severe implications on
whether the standardised TB regimen as accepted and prescribed
worldwide is indeed falling short, and instead of curbing, is actu-
ally fuelling the growth of resistance.19 He advocated the need to
look at the interactions in the genomes, especially into why some
strains are more suited to existing with the mutations and find it
easy to accumulate and survive the defects related to these abilities.
Moving toward the host’s end of the spectrum, this disease
manifests itself in several forms - latent, pulmonary and dissemi-
nated, to name a few. Strain association with the disease form has
been noted as in the case of Beijing strains being incriminated for
a majority of the disseminated TB cases. An investigation to char-
acterize the predominant strains of M. tuberculosis infecting the
population in the Amhara region of Ethiopia was undertaken by
Dr S.A. Yimer et al., Oslo University Hospital (Norway).20 A
cross-sectional study of 240 sputum samples revealed the Central
Asian strain to be the most predominant. However, the most
striking finding of the study was the discovery of lineage 7 in this
region. Whole genome sequencing (WGS) of lineage 7 places it
between the modern and ancient lineages. The lineage has been
stable over a long period of time and has started to diversify only
recently for reasons unknown. Patient information reveals that
this strain is associated with those who show delay in seeking
treatment.20 This strain grows slower in vitro as compared to the
other strains and the lack of pathogenicity resulting in milder
symptoms which may explain the delay of patients in seeking
treatment. However, it is this shortcoming that gives the strain
an advantage over others as untreated patients keep transmitting
it further as is evidenced by clustering of incidences by Tessema
et al.21
Yet another burning issue is that of the lack of a simple, inex-
pensive, gold standard test for the detection of pyrazinamide
(PZA) resistance in M. tuberculosis. PZA was introduced to anti-
TB therapy in the 1980’s. It targets the dormant or ‘persister’
subset of the infecting microorganisms and was thereby crucial in
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shortening the therapy course from 9 months to the current
6-months regimen.22,23 Though its mechanism of action and
development of resistance against it is fairly well-understood,
identifying drug resistant cases is still cumbersome.24 Dr D.A.
Maslov, Russian Academy of Sciences (Russia) and team, under-
took a study to understand the prevalence of PZA-resistance in
the MDR population of the European region of Russia. Three
different techniques, namely the BACTECTM MGITTM 960
PZA Kit, Wayne PZase activity assay and sequencing the genes
controlling PZA resistance (pncA, panD, rpsA), were used to iden-
tify the resistant mutants.25,26 Although all the techniques missed
a few cases, detection by BACTECTM MGITTM remained the
method of choice as it had the best combination of sensitivity
and selectivity compared to the others. Among the 519 MDR
isolates collected in this study, over 70% were found to be PZA-
resistant (unpublished data). Interestingly, the authors found one
PZA-resistant isolate lacking mutations in all 3 known PZA-
resistance associated genes.
Thus, there is a need for tight connection between genomic
and microbiological level investigations that can serve to feed
information to each other. A concerted approach is of paramount
importance to understand this multi-faceted organism better and
to reveal the chinks in its armour that can be exploited for diag-
nosis as well as therapy.
TB and its murky associates
The high rates of TB co-infection in HIV positive patients has
been established by studies conducted in Africa which bears a
high burden for both the diseases.27 On the other hand, diabetes
mellitus predisposes the patient to develop active TB and severely
affects the treatment outcome such that individuals suffering
from the former condition are twice as likely to die from the lat-
ter disease.28,29 Diabetes, a condition usually identified with
affluent countries now also has a greater stronghold in low and
middle-income countries where HIV and TB are already ram-
pant.30 Dr A. Wafi, Aligarh Muslim University (India) spoke
about the significance of Th1 and Th17 cells as markers in TB
patients with diabetes mellitus. Both are subsets of T-cells and
are strongly involved in the host’s cell-mediated immunity and
produce inflammatory effectors, or cytokines as a response to
external agents. Elevated levels of these T-cells and IFN-g were
found in patients suffering from both diabetes and TB when
compared to those with only TB. It was suggested that diabetes is
associated with alteration of the immune response to TB leading
to a biased treatment outcome. Thereby prophylactic treatment
against TB to all diabetic patients with LTBI was recommended
by the speaker.
WHO (http://www.who.int/en/) and The Union (http://
www.theunion.org/) together, have published policy documents
regarding the key guidelines for further research to strengthen the
understanding of the association between diabetes and TB. How-
ever, none of the meta- and systematic reviews available in pub-
lished literature includes African populations. Though there is no
reason to suspect a difference of the disease associations in differ-
ent ethnicities, the high prevalence of HIV in these populations
does present a further complication. Dr S. L. Bailey, London
School of Hygiene and Tropical Medicine (UK), has been look-
ing into the modifying effect of HIV on the association between
hyperglycaemia and active TB in Lusaka, Zambia. A case-control
study sampled 3000 TB and 7000 non-TB (sputum culture neg-
atives) cases obtained from the regional TB clinics of 3 commu-
nities. Diabetes among these individuals was diagnosed via RBG
(random blood glucose) concentration and the results showed
that a low percentage of the TB patients examined were hypergly-
caemic and a similar proportion was found among the controls.
This low prevalence of hyperglycaemia goes against the trends
seen elsewhere; there seems to be no association between TB and
hyperglycaemia in the HIV negative patient group. This is
sharply reversed in the HIV positive group where a strong associ-
ation is seen between the 2. Only at elevated levels of hypergly-
caemia (>11.1 mmol/L) was the difference really noticeable.
However, newly diagnosed TB-patients, often weakened by the
disease condition commonly exhibit a stress-response, which can
manifest itself as hyperglycaemia.31,32 As a consequence it was
necessary to discriminate between the proportion of the patients
that were hyperglycaemic due to diabetes mellitus and those with
stress-induced hyperglycaemia. A subset of the previously studied
TB cases was selected and RBG, FBG (fasting blood glucose) and
HbA1c concentration at the time of TB diagnosis was measured.
As a reference standard test, FBG concentration was measured
post initiation of treatment. Comparison of the different diag-
nostic results showed that roughly half of the RBG and FBG-
detected hyperglycaemia cases were diabetes related. These results
show that most patients with HIV had stress-induced hypergly-
caemia. In light of this information, the initially striking correla-
tion of the HIV positive diabetics with active TB infections
proved to be insignificant. Overall, the study revealed no evi-
dence of association between hyperglycaemia and active TB in
sub-Saharan Africa. These findings are in stark contrast with the
TB-diabetes relation found in other parts of the world.33-35
Not only do other diseases put patients at risk of contracting
TB but those with active pulmonary TB have increased chances
of developing mycosis as well. Co-infections with Cryptococcus
spp., Coccidiomyces spp and Histoplasma spp. have been recorded
since the late nineteenth century. Whether the infections occur
concurrently or sequentially does not affect treatment the out-
comes.36 However, diagnosis and treatment of these infections
together is complex as discussed by Professor R.P. Mendes,
UNESP (Brazil).37 As the symptoms of most of these fungal
infections imitate that of pulmonary TB, these may lie undetected
for a while. Once identified however, initiation of the classical
anti-TB and anti-fungal therapy usually results in a worsening of
symptoms as these drugs interfere with each other. Drug replace-
ments such as using moxifloxacin instead of rifampicin or rifabu-
tin and itraconazole for posaconazole were suggested. However,
treatment of TB in these cases remains of utmost importance as
control of its transmission is a common, global priority. Emphasis
was laid on expanding our understanding of the drug-interactions
and increasing the arsenal of drugs currently available today.
Tubercular infection of the central nervous system (CNS),
often known as TB meningitis (TBM) is a serious and life-threat-
ening condition. It accounts for up to 5–10% of all the TB cases
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worldwide but is responsible for more than 40% of the deaths
due to TB.38 TBM is characterized by varied clinical manifesta-
tions such as, those without tuberculoma or infarct; those with
either tuberculoma or infarct; and those with both. Patients with
tuberculoma are difficult to treat because the disease persists even
with anti-TB therapy and invasive treatment can lead to severe
complications. Data regarding prognostic value of tuberculomas
has been limited with conflicting evidence.38,39 It is believed that
patients with tuberculoma have the worst prognosis but Prof. M.
Wasay, Aga Khan University (Pakistan) pointed toward several
other factors that were better indicators of treatment outcomes in
these cases. Though factors such as hydrocephalus, advanced age
and active TB infection appeared to indicate poor treatment out-
comes; he observed that infarctions, either chronic or acute, serve
as very good determinants for prognosis. Follow-up MRI scans
to monitor the evolution and progression of the disease phase
may help in identifying new infarctions and the response to med-
ical intervention. Prof. Wasay recommended stroke prevention
in CNS TB as the most important area requiring consideration
as a reduction in this can substantially lower the number of
deaths owing to CNS TB. The role of aspirin and high dose ste-
roids in CNS TB has been debated.40,41 The predisposing and
protective factors for tuberculoma formation in CNS TB are lit-
tle understood. In addition, the duration of anti-TB treatment
varies case-by-case and little is known about stroke prevention in
these cases. The speaker raised the questions in areas where there
is little knowledge regarding strain, virulence, resistance patterns,
host factors associated in increased risk for CNS TB. He called
for more randomized control trial studies to be done and increase
in collaboration, funds and capacity for this area to improve
understanding and ultimately improve management of CNS TB.
Zoonotic nature of the Mycobacterium species
The pathogenic species of Mycobacterium are notorious for
causing zoonoses, infectious diseases of animals that can be
spread to humans.42 M. bovis is an infectious, slow-growing path-
ogen responsible for causing TB in cattle and is also a part of the
M. tuberculosis complex, causing the disease in man.43 Due to the
development of pasteurisation techniques, the incidences of TB
in humans due to M. bovis has decreased substantially over the
years. However, this disease continues to plague cattle, with UK
having the highest bovine TB incidence in all of Europe. There
has been a significant increase of bovine TB cases from 1076 in
1996 to 4720 infected animals in 2014.44 An estimated half of
these herds are infected by badgers (Meles meles) that serve as the
natural reservoir of this pathogen. The first badger harbouring
M. bovis was reported in the early 1970s.45 Since then, the Bad-
ger Protection Act (consolidated in 1992) has served to protect
and preserve this species of animal.46,47 Currently, UK has the
highest concentration of badgers in Europe and up to 30% of the
badgers in a region can be expected to harbour the TB bacilli.
The route of transmission of the bacteria to cattle has not been
established yet.
Vaccination of cattle is illegal in the EU, as after administra-
tion of BCG, there are no means to discern between a vacci-
nated and an actively infected animal due to the cross-reactions
routinely faced while using the TST as a diagnostic tool.48
Therefore control measures are limited and usually involve
annual surveillance, removal of infected animals and control of
cattle movements (physical barriers).48 Badger vaccination is
suggested by Dr S. Lesellier, Animal and Plant Health Agency
(UK), as a means to reduce the prevalence and severity of
bovine TB in a badger population and thereby reduce the rate
of transmission in cattle. BCG vaccine has been proven safe in
humans; it is inexpensive and readily available. However,
acquiring a license (obtained in 2010) for its use in badgers
required 10 years of exhaustive studies to demonstrate the safety
and efficacy data for using BCG in captive and wild badgers.48
Demonstration of safety and efficacy of the vaccine was done by
2 studies that used 17 intra-muscularly and/or subcutaneously
vaccinated badgers among which 8 were given the dose allowed
for humans and the rest received a higher dose.49 Six unvacci-
nated badgers were used as the controls. Seventeen weeks after
vaccination, the badgers were infected with M. bovis directly in
situ by endobronchial instillation in the right middle lung lobe
using a flexible fibroscope. Samples taken for immunology and
culture were removed at regular intervals and 12 weeks after
infection the animals were sacrificed followed by detailed post
mortem examination. A statistically significant reduction in the
disease burden was observed when higher dose was used for vac-
cinating the badgers. Excretion of M. bovis from the trachea was
also found to be lower in number and appeared later in the
timespan of the infection. Badger-specific IGRA assays revealed
higher levels of IFN-g in the animals that received a higher
dose. However, post-challenge the levels of IFN-g normalized
for all probably making a case that it may not be a reliable
marker to estimate protection.
The observational studies to collect the safety and preliminary
efficacy data from the wild badger population spanned over
3 years: animals were trapped, vaccinated or kept as non-vacci-
nated controls, microchipped for identification and monitored
over time. No animal was sacrificed, therefore post mortem data
are not available, and instead 3 live tests were conducted. A high
prevalence of TB was found in the badger populations pre-study,
but a highly significant reduction of up to 3-quarters was
observed in incidence at social group levels. Further analysis of
data identified an indirect, protective effect in unvaccinated cubs
when more than a third of their social group had been vaccinated.
This is probably due to the ‘ herd effect’ , but the same wasn’t
recorded in adult badgers. As seen with other species, BCG,
though effective, is not a 100% eliminator of the risk of infec-
tions. However, a 75% protection rate justified the issue of a
license for the use of BCG in badgers. The next progression of
this study would be to develop an oral vaccine for badgers. This
would remove the need to trap and vaccinate individual badgers
while reaching a larger number of animals and could be poten-
tially cheaper. However, this will require an oral vaccine that pro-
duces consistent protection in badgers, equivalent to that seen
with the injectable vaccine. In addition, palatable bait, the best
means to deploy the vaccine for maximum uptake and the impli-
cations of this vaccine on human health and the environment
need to be established. Though there are oral vaccine-candidates
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available, obtaining a license and transferring the technology to a
manufacturer for scaling up production will still require a good
part of a decade.
It is speculated that TB may have infected the mastodon,
however the first established case was reported in 1875 at the
London Zoo.50 By the late 20th century it was recognized world-
wide though no studies have been done to estimate their global
prevalence. The rise of TB in captive elephants in the USA was
discussed by Dr J. Landolfi University of Illinois (USA). Pres-
ently, there are 55 culture-confirmed cases of TB in elephants in
the United States of America. A majority of these cases are due to
M. tuberculosis and sparingly due to M. bovis. The infection is
manifested as a chronic, subclinical infection with severe dissemi-
nation. Unfortunately, most cases only get documented post
mortem. As a result, about 65% of the infected animals are now
deceased. In addition to the concern regarding the health of the
animals, there are strong indicators that it may be transmissible
from the handlers and vice versa. The high prevalence of TB
among humans in Southeast Asia indicates that in this case, it
may be that humans serve as the reservoir infecting the Asian ele-
phants, which appear to be more susceptible to it. Differences in
the immune functions of this population of elephants may serve
to explain the presence of a special susceptibility toward the path-
ogen. However, issues regarding the lack of reliable diagnostics,
efficacious treatment regimens and understanding of the mecha-
nism of the underlying disease appear to be universal across host
species.
For an understanding of the physiology of the disease progres-
sion, Dr Landolfi’s group looked at formalin-fixed, paraffin-
embedded sections of lung from captive north American and
Asian elephants.51 Latent lesions were found to be well organized,
discrete granulomas, with many activated macrophages and
CD3C T-cells. Histologically, in the active TB cases there were
widespread, poorly granulomatous lesions. Inflammation was
found to be centered on regions of necrotic debris with a low
number of macrophages and lymphocytes mostly of the B-cell
type.
Reverse transcriptase PCR to detect the mRNA levels of cyto-
kines from unstimulated peripheral whole blood samples from
106 captive elephants was studied.52,53 No statistically significant
differences were observed between the TB positive and negative
elephant samples. However, incorrect diagnosis while selection of
the elephants, lack of information on the disease stage and the
use of unstimulated blood could have had an impact on the
results seen. As an improvement, mycobacterial antigens such as
PPD, and CFP10 were used with ConcA as a control to stimulate
peripheral blood derived monocytes. These studies showed ele-
vated mRNA levels of TNF a, IFN g as well as IL-17 in the TB
positive elephants with PPD-B acting as the best stimulant.54
Detection of TB in elephants relies on trunk wash procedures as
both TST and X-ray analyses are not feasible. Though serodiag-
nosis is being pursued now, the low and availability of these tests
remain an issue. Dr Landolfi hopes for the whole blood assay to
have similar or better sensitivity and specificity than the current
gold standard technique, the trunk wash, which is a labor inten-
sive method. She warned that the advancements in detection of
the disease would have to be paralleled with assessment techni-
ques for response to treatment as well as development of a more
suited treatment regimen for elephants.
Understanding the human response to TB: insights for
diagnosis and monitoring patients
Rapid assessment of the response to TB treatment in humans
at present is a considerable road-block and accurate methods to
do so can have a definitive impact on treatment outcomes. Cyto-
kines play a major role in protection against mycobacterial infec-
tions and regulate the immune response at a cellular level. TNF
a, IL-12 and IFN g are the common cytokines that have been
investigated in vitro but there are very few in vivo studies carried
to assess their role as early treatment biomarkers for MDR-TB.
N Fatima, Aligarh Muslim University (India) took up a study to
determine the correlation between cytokine levels in the pulmo-
nary and extra-pulmonary TB patients. A total of 65 blood sam-
ples were collected from a cross-section of TB infected patients
and controls. The results showed an increased TNF-a level was
seen in new TB cases and in MDR patients meanwhile no signifi-
cant rise of IL-4 in new TB patients.55 The analysis of the various
cytokines revealed that these cellular responses may indeed be dif-
ferent in new TB, MDR patients and patients with extrapulmo-
nary TB. Hence, these could serve as biomarkers for the response
to TB treatment and is therefore important for both clinical prac-
tice (in the detection of MDR TB cases) and clinical trials of new
anti-TB drugs.
Exploiting the often ignored humoral immune response to
mycobacterial antigens was suggested by Emeritus Professor PK
Das, University of Amsterdam (The Netherlands). He pressed
that these responses can be identified by electrophoretic techni-
ques and can help in differentiating between mycobacterial infec-
tions and also detecting the stage of the disease.56 The differences
in the type (IgG, IgA) of antibody and their pattern as seen on
electrophoreses, can conclusively predict infection by
mycobacteria.57
One of the greatest impeding forces to vaccine developments
against TB is the lack of known antigens that could selectively
prime the host’s immune system toward pathogenic mycobacte-
ria. Alternatively, identifying a response to a specific antigen in
an infected individual could also serve as a robust diagnostic tool.
In an effort to identify potential antigens, Dr AJ Minnaard,
University of Groningen (The Netherlands) extracted all the lip-
ids of the outer layer of mycobacteria and identified those present
only in the pathogenic species.58,59 These glycolipids get picked
up by our immune systems, especially by the CD1 system pro-
ducing immunogenic responses and thereby providing protection
to the host.
These compounds are difficult to extract due to the slow
growing rate of the pathogens, but can be prepared organically.
All compounds contain a polar head such as a trehalose, mannose
or a complex tri-saccharide. They also comprise of a non-polar
tail which is very waxy in nature. New synthesis tools incorporat-
ing new catalysts had to be developed for their synthesis.60 In an
iterative process the stereo methyl groups were added with a qual-
ity check at every step followed by extensive characterization to
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confirm the product.61,62 This effort required 40 years since the
isolation of the compound from the mycobacterial cells and has
currently received support from the Bill and Melinda Gates
Foundation.
One natural product of M. tuberculosis, the 1-tuberculosinyla-
denosine (1-TbAd) lipid is composed of a diterpene unit linked
to adenosine. A screen for 1-TbAd mutants, complementation
studies, and gene transfer identified Rv3378c as essential for 1-
TbAd biosynthesis.63 This gene is associated with virulence and
its deletions fail to prevent lysosomal maturation and acidifica-
tion in macrophages.64
A strong, fundamental understanding of the host-pathogen
interactions taking place during infection is essential to inform
both diagnostic and preventative therapeutics research. The anti-
gen profiles of the pathogen at its various physiological stages
need further elucidation as does the cytokine, serological and cel-
lular responses of the host.
Surgical interventions for alleviation of TB
In the 1880s, thanks for Carlo Forlanini, lung collapse ther-
apy or artificial pneumothorax, became the treatment of choice
for pulmonary TB as the world still awaited the discovery of anti-
biotics.65 As antibiotic resistance now grips the globe, attention
is being re-focussed on the role of surgery in the management of
active TB infections.
Extra-pulmonary TB in the thoracic cage can include infec-
tions of the lymph nodes, the pleura, chest wall, and so on.
Detection of these cases is difficult and often tissue diagnosis is
required. Though the role of surgery in TB remains mostly diag-
nostic, Prof K.M. Al-Kattan, King Faisal Specialist Hospital &
Research Center (Saudi Arabia) suggested using it for treatment
as well as palliative treatment. Several procedures such as simple
drainage to more complicated ones such as wedge excision lobec-
tomy, pneumonectomy, mediastinal lymphadenopathy and thor-
acoplasty were discussed. As surgery is an extreme measure and it
is mandatory that the patient has been on anti-TB therapy for at
least 3 weeks prior to the operation. This route is undertaken
only when there are added complications such as non-responsive
MDR TB housed in fibrotic structures that preclude treatment
or involvement of fungal infections. However, in spite of all stan-
dard precautions being taken, morbidity due to blood loss and
post-op complications remain high. In some cases though, sur-
gery is inevitable as infections of the chest wall result in eroded
sternums that require complete restructuring. Enlarged lymph
nodes in children can compress the mediastinum and in these
cases surgery can only partially resolve the condition.
Arthritic TB of the spine was first described by the British sur-
geon, Percivall Potts and is now known as the Pott’s disease. It is
a secondary localization of pulmonary TB, which in its acute
phase forms abscesses capable of causing damage to the vertebrae
and discs. It can lead to severe vertebral deformities (scoliosis and
kyphosis) which may result in disabling compression of the spinal
cord and neurological complications.
It is an extrapulmonary form of the disease that results in
excessive back pain leading to tissue and vertebral damage. The
best remedy for these cases, as advocated by Dr S. Rigotti,
Ospedale Sacro Cuore (Italy), is a strut grafting procedure as it
allows for healing and spinal fusion required for maintenance of
spinal stability (kyphotic angle). Early detection is the key for
success of this procedure. Once detected through MRI, percuta-
neous abscess drainage procedure is carried out and the fluid
obtained is sent for DST. Following the operation, long bed rest
of up to 12 months is necessary followed by the use of a brace for
another 18 to 30 months. Anti-TB therapy comprising of an ini-
tial 2 months of RIF, INH, EMB, PZA, followed by 10 months
of only INH and RIF is usually followed. Once the infection has
been treated, an operation to correct the effects of drainage on
the spine has to be performed. The stabilization operation
involves screws inserted into the vertebrae. An extended follow-
up period of 2 years ensures total recovery of saggital balance and
frontal stability of the patient. The procedures are minimally
invasive with little risk to adults, however the situation becomes
complicated in children below 12 years of age as their bones are
not ossified and infection is usually detected much later in its
progression.
Treatment of TB: successes and failures
Though an established and effective treatment against the sus-
ceptible forms of TB exists, the decline of the deaths due to TB
seems to have plateaued in recent years.66 This could be because
of the emergence of the drug resistant variants of the pathogen,
which claim the lives of around half of the patients they infect
depending upon the diagnostic and treatment facilities available
to the patient.67–69 Though MDR TB remains a minor portion
of the total TB worldwide, the rate of notified cases has remained
unchanged over the past 5 years at 0.3 per 100,000. As diagnos-
ing resistance is especially difficult, this may not reflect the real
numbers. While discussing their successful results of MDR/XDR
TB treatment, Dr T. Van der Werf, University of Groningen
(The Netherlands), mentioned the need to incorporate the treat-
ment outcome results into scientific analyses. He brought to
attention that MDR is not a homogenous disease and shows a
gradient of severity which, in effect, progressively restricts the
available treatment options. Further complications arise from the
fact that the dose of drugs achieved in patients varies from one to
the other. Insufficient drug exposure or inadvertent monotherapy
result in emergence of resistant organisms, an event made more
likely when using a relatively weak second line drug.
Using a treatment structure that was individualised for
patients but still following WHO guidelines, Dr Van der Werf
reported a favorable outcome in 85.6% of patients treated for
MDR-TB between 2000 and 2009 using 18 month treatment
plans. These included using higher doses of class 5 drugs than
conventional practice, including linezolid and Clofazimine in the
regimen, the latter of which was described by Dr Van der Werf
as a promising addition. Therefore, based on their promising
outcome results he suggested the use of drugs at doses above the
recommendations and accompanied by close observation of the
patient.70,71 Unknown drug interactions are one of the reasons a
‘one size fits all’ treatment regimen does not work. Highlighting
the lack of randomized, controlled trials to guide antimicrobial
treatment for MDR TB, Dr van der Werf mentioned that the
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single best predictor for efficacy of any antimicrobial drug is eval-
uation of the drug exposure relative to susceptibility of the
organism.
Anti-TNF therapies for rheumatism have been very effective
and have led to the development of several artificial monoclonal
antibodies such as infliximab and rituximab that act as TNF ago-
nists. However, TNF is pivotal in the immune response to M.
tuberculosis and helps contain the infection.72 Therefore, the use
of these agonists may increase the risk of patients developing TB
or other complications from infections by non-tuberculous
mycobacteria. Keane et al. showed that there were 70 reported
cases of TB, usually extra-pulmonary, from the 147,000 patients
administered with infliximab worldwide between 1998–2001.73
Almost all of the TB cases were reported in countries with low
incidence of TB making this association a highly alarming one.
Etarnecept, another TNF antagonist was found to fare marginally
better than infliximab and adalimumab, but the TB incidences
still remain high.74,75 Professor O.M. Kon, Imperial College
Healthcare NHS Trust (UK), highlighted the probability of
most of these cases being LTBI that are activated as the host
immune surveillance drops and recommend testing for it before
initiating treatment for rheumatism. Therefore diagnosing LTBI
in these patients is a high priority. Patients are usually risk-
assessed, taking into account the risk of prophylaxis versus devel-
oping TB and then put forward for diagnosis. However, risk
stratification misses 2-thirds of the cases thereby lowering the
sensitivity manifold. For diagnosis, chest X-rays, TST and IGRA
are the methods of choice. The TST can be used for diagnosis
but patients with rheumatism usually have an attenuated
response to the test.76 IGRAs in this case are highly specific for
the detection of LTBI unless steroids are administered to the
patient. In the absence of guidelines for practitioners, Professor
Kon suggested a thorough follow-up and surveillance of patients
by taking into account their contact and travel histories as treat-
ment with biologics has been noted to be associated with reacti-
vation of TB many years post cessation of treatment.
Treatment of TB: a new way forward
As the pathogen develops new mechanisms to get past the
drugs meant to kill it, development of antibiotics with novel
mechanisms of action become imperative. With a view to exploit
the mycobacterium cell’s requirement for iron, Dr M.J. Miller,
University of Notre Dame (USA) discussed the potential of spe-
cies-specific siderophores or mycobactins as potential antibiotics.
Mycobacterial cells have an obligatory requirement for iron
(III) which is assimilated from the environment with the help of
siderophores secreted by the cells. All organisms have slightly dif-
ferent siderophores with mycobacteria having 3 types.77 Interest-
ingly, these siderophores, or mycobactins from one organism can
antagonise the growth of another and thus show potential for use
as antibiotics.78 Additionally, attaching a deleterious group to
the mycobactin of a species converts it into a Trojan horse that
serves to kill the organism effectively as seen when artemisin is
attached to mycobactin T.79,80 These antibiotics are extremely
specific, however synthesising them is not practical. Thus, high-
throughput screening of small fragments of the mycobactins and
their derivatives were undertaken. Only the oxazolines formed
from the fragments showed activity against the pathogen. Sur-
prisingly, these compounds had no role in iron transport. They
were also found to be metabolically unstable.81 The amides of
these compounds were more stable but lost their activity against
M. tuberculosis. Investigations of the structure activity relation-
ships led to the synthesis of pyridine compounds that are meta-
bolically stable with highly improved activity. Over 500 analogs
of the compounds have been synthesized and have been found to
have very good biological activity against drug resistant strains of
the pathogen as seen in mouse models.82 The active compounds
are believed to target cytochrome C oxidase and shut down respi-
ration of the mycobacterium. The low MICs in the nanomolar
concentrations and the reasonable space to tune the compounds
to improve their pharmacodynamic/kinetic properties do indeed
raise hope for a new drug against TB in the near future.
Looking to plants for inspiration, Dr M. Baltas, The Center
National de la Recherche Scientifique (France) and his group,
investigated the potential of cinnamic acid derivatives. One of
the derivatives incorporates isoniazid and another has a styryl tri-
azolophtalazine frame. The latter showed very good activity even
against INH-resistant M. tuberculosis. Following these successes,
a 2-step library of around 200 compounds were made containing
aromatic rings with different linkers and hydroxyl groups. Tria-
zoles, representative of the triclosan systems, and pyrrole deriva-
tives were made and found to have similar activity against the
pathogen.83,84 Treatment of mycobacteria with these com-
pounds, specifically, their lead compound TB09 reduced the cell
wall mycolates thereby showing evidence that these compounds
act on trehalose dimycolate and interfere with the cell wall
assembly.
Natural products are also an extensive source of novel chemi-
cal scaffolds from which novel anti-tubercular agents with pleio-
tropic modes of action can be discovered as was discussed at the
poster presentation sessions.85–90 To considerably shorten the
time of development of a molecule from bench-to-bedside
another feasible strategy is to repurpose existing drugs used clini-
cally for other conditions or comorbidities. The potential of
repurposing non-steroidal anti-inflammatory drugs (NSAIDs) as
anti-tubercular therapy was discussed and also gathered serious
consideration.91-95
Moving on to fragment-based approaches to develop inhibi-
tors of mycobacterial growth, Dr E. Polycarpou, Kingston Uni-
versity (UK), spoke about inhibitors designed against enzymes
required for cholesterol metabolism. Cholesterol is required dur-
ing various stages of the bacterial life cycle-phagocytosis, bacterial
inhibition of lysosome maturation and bacterial replication
within macrophages.96 Transcriptomic and gene deletion mutant
studies reveal hsaD gene in the cholesterol catabolism operon in
M. tuberculosis to be essential for survival within macrophages
and therefore a key target.97 HsaD is a stable enzyme that cleaves
the C-C bond through serine/threonine protease-like catalytic
triad.98 Mechanism-based inhibitors of the enzyme showed poor
selectivity and/or aqueous solubility and therefore a fragment-
based approach was adopted. The rationale behind this approach
is to identify low affinity scaffolds that can then be combined to
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increase selectivity and effectiveness of the inhibitors designed.
A library of 1260 fragments was screened using differential scan-
ning fluorimetry to evaluate their binding affinity to HsaD.
Seven initial hits were then verified using a high-throughput col-
orimetric assay developed in their lab. X-ray crystallography
enabled in resolving the structures of 2 fragments and under-
standing the binding sites of the fragments on the enzyme. Struc-
ture-activity relationship further helped refine the fragment
structures to inhibit mycobacterial growth specifically while
being non-toxic to mammalian cells and E. coli.
Arylamine N-acetyl transferase (NAT) was found to be pres-
ent in humans serving to detoxify drugs.99 It was also found to
be present in mycobacteria where it appears to play a significant
role in mycolic acid synthesis and the proper assembly of the cell
wall.100 A rapid, colorimetric screening method to detect the
activity of the enzyme enabled screening of a large number of
fragments.101,102 Two promising fragments were identified, one
being a prodrug and the other binding directly to the enzyme
and faring better at eukaryotic cell toxicity than the former. The
latter compound was found to be more effective than INH and a
few derivatives have been designed. The NAT inhibitors are cur-
rently under license to Eli Lilly from Summit PLC.
Toxin-antitoxin (TA) modules comprise of 2 genes where the
upstream antitoxin abrogates the effect of the cognate toxin
which targets an essential cellular function. The post-genomic era
has revealed that these modules are diverse and ubiquitous. These
TA are found in pathogenic mycobacteria, except M. leprae but
not found in non-pathogenic ones. 88 putative TA systems have
been identified in M. tuberculosis H37Rv out of which 40 have
been found to be functional. ParDE2 is a putative TA module
that was investigated by M. Gupta, Jawaharlal Nehru University
(India). RNA transcript analysis of the M. tuberculosis demon-
strated that the genes were transcribed and hence not pseudo-
genes. In cells overexpressing only the toxin ParE2, growth was
inhibited but the cells remained alive thereby becoming viable but
non-culturable. Microscopic images of these cells revealed elon-
gated phenotypes with an extended periplasmic space and corru-
gated rough membranes enclosing several vacuolar structures.
ParE2 was expected to target the DNA gyrase mechanism.
DNA gyrase is made up of 2 subunits, A and B that uncoil the
DNA molecule by cleaving one strand passing it around the other
and ligating it back. Purified mycobacterial DNA gyrase subunits
A and B were obtained and investigations with the holoenzyme
revealed that the toxin most likely interferes with the ligation
step. The C-terminus of ParE2 was found to interact with GyrB
and a 20 amino acid deletion abrogated its toxicity. When trans-
formed M. smegmatis cells containing the TA module were used
to infect THP-1 cells, those expressing the wild-type toxin
showed lowered bacterial loads within the macrophages. On the
other hand, the ones with truncated versions of the toxin showed
cell viability at par with the non-transformed controls. This
points to the hypothesis that, under stress conditions the bacteria
produce proteases that act upon the antitoxin thereby allowing
the toxin to have its effect on the cell which shifts to a VBNC
phenotype inside the macrophage. Additionally, ParE2 express-
ing E. coli cells demonstrated increased tolerance toward
antibiotics, surviving well over the established minimum inhibi-
tory concentrations.
The growth of antibiotic resistance and the subsequent short-
fall in the number of effective drugs available for treatment pro-
vided the much need incentive for expanding research into
antimicrobial drug discovery and design. It is encouraging that
scientists have identified and are investigating several alternative
routes to identify these molecules starting from the microbes
themselves to plants and synthetic molecules.
Raising consciousness toward TB: in public
and specialists alike
The TB burden in children is estimated to be in the range on
4–21% of the total burden depending on the country.103 Bangla-
desh, a high burden country, reports only around 3% of its total
disease burden owing to childhood TB.104 This discrepancy sug-
gests that Bangladesh fails to detect TB in approximately 15,000
children annually. A survey of the regions showed that the sub-
district hospitals had low rates of diagnosis probably owing to
the low clinical capacity and lack of skilled healthcare workers in
the regions. Therefore in 2012 a guideline was laid out for the
training and modular capacity-building of doctors and health
care workers. It contained training modules, facilitator’s guides,
flip charts and training videos. The objectives and achievements
of this approach in Bangladesh were shared by Dr S. Ahmed,
Shaheed Suhrawardy Medical College (Bangladesh).
The main challenges in developing the modules were taking
into account the varied age and skill ranges that the materials had
to cater to. A comprehensive and generic training module was
drafted based on the local case data available from the country’s
records. With the support of USAID under the guidance of
National Tuberculosis Control Program (NTP), Bangladesh
Pediatric Association (BPA) TB care II started the training from
November, 2013. Seventeen districts and 122 sub-districts servic-
ing a population of around 150 million were covered. The mod-
ule was designed to have various components such as, personal
reading, peer reading, group tasks, case demonstration and case
solving. All the participants of the training went through a pre-
training test and post-training test comprising of 20 questions.
The results of the 2 tests showed a significant increase in knowl-
edge after the training sessions irrespective of the initial skill,
experience and age of the participants. The training was com-
pleted on 2nd July 2014 and records since then show that child-
hood TB diagnoses in Dhaka have increased. However, in some
areas the detection has gone down or is still far from the expected
numbers showing that training can resolve this issue only in part
and that a reliable diagnostic tool for those below 4 years of age
is necessary.
Developments in any field of research require a steady inflow
of investments and grants. To achieve the decrease in the rates of
mortality and incidences that have been set as goals by the Stop
TB partnership (http://www.stoptb.org/) and the WHO, greater
investments are required. This can be attracted only be raising
and sustaining the profile of TB by ensuring heavy political
involvement. The cost of antimicrobial resistance is estimated to
be around US$ 100 trillion by 2050 as highlighted by Dame
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Sally Davies, the Chief Medical Officer of the UK. A similar cost
analysis of TB including the cost to the agriculture industry could
be the key to grabbing public attention. A systemic analysis of TB
research in the UK in the period between 1997 and 2013 was car-
ried out by Dr. M. Head, Infectious Disease Research Network
(IDRN, UK; http://www.idrn.org/) and his collaborators. Funds
received by UK institutions for infectious diseases research was
mapped for an initial period between 1997–2010.105 This
included human infections only, unless zoonosis was demon-
strated. The data was sourced directly from the donor’s records
and the awards were normalized by converting international cur-
rency to GBP sterling and adjusted for inflation. Studies were
categorised based on the disease area, clinical specialty, specific
infection, R&D value chain (clinical trials phases, etc). Around
7400 grants were awarded over 1997–2010 and 1228 from
2011–2013 with a total investment of approximately 3.7 bil-
lion. Medical Research Council (MRC), UK and the Wellcome
Trust were revealed as the top donors while HIV and malaria
received the most funding. This is disparate to the disease bur-
den, where TB research received only 6% of the total amount
awarded.
In the initial years of the analysis, pre-clinical science received
higher funding but there appears to be a slight shift toward fund-
ing the clinical phase trials of drug development in the recent
years. More awards for translational research, product develop-
ment, diagnostics and vaccine therapy was observed as well.
As a leading investor in global infectious disease research, UK
has been investing relatively well in TB but an increase in funding
is required. A look into the costs, burdens and the funding biases
of other world economies in infectious and non-communicable
diseases could inform policy makers and funding bodies and
assist in the identification of research gaps and priorities.
Conclusion
Battling this scourge of the past that has firmly found a place
in the current times requires co-ordinated action from workers in
the laboratory to those out in the clinics. This meeting nurtured
intense and focussed scientific dialog that promises to seed long-
lasting collaborations, or at the very least, raise awareness and
educate. Impassioned pleas from all the speakers resonated the
similar theme that prevention, diagnostics and treatment need to
be strengthened. As fundamental research gains focus, it is impor-
tant to note that antibiotic resistance in itself is on its way to far
greater notoriety than TB and needs immediate attention from
policy makers, pharmaceutical companies and scientists alike. It
is encouraging that early-stage researchers are acknowledging the
need for increased interdisciplinary approaches and communica-
tion. Noble efforts such as the IDRN (UK) aimed at increasing
the capacity of research need to be applauded and supported.
Advances in the field of vaccine development are apparent in
that 11 candidates that were either BCG replacements or boosters
were in clinical trials in 2010.106 In the absence of reliable bio-
markers to predict the protection offered by vaccines, large-scale
human efficacy trials is the only option to evaluate a vaccine.
These studies need to be further refined as there are many factors
such as age, ethnicity, gender bias of the cohort that could affect
the outcome of the trials.
Under or mis-diagnosis of TB has been instrumental in the
spread of MDR- and XDR-TB. The Stop TB Partnership has
thus called for immediate action for the production of new diag-
nostic techniques for rapid identification of drug susceptible and
resistant TB as well as LTBI.107 Dorman suggests moving from
culture-based techniques as any such tool will only produce incre-
mental gains on the currently existing methods of diagnosis.108
With the advent of the IGRAs, PCR- and line probe-based
assays, the search for diagnostics appear to be on track.
Finally, after half a century of no new drugs to treat TB, the
drug development pipeline now contains a number of novel and
repurposed drug candidates.109 This improvement of the situa-
tion is however, far from the one desired considering the high
attrition rates of candidates in drug trials as well as the well-
equipped opponent we are faced with.
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